NCT05900648View on ClinicalTrials.gov

Regorafenib and XmAb20717 in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy (RX-CROME)

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

May 17, 2023

Primary Completion Date

February 9, 2024

Study Completion Date

February 9, 2024

Conditions
Colorectal CancerColon CancerRectum Cancer
Interventions
DRUG

Regorafenib

Given by PO

DRUG

XmAb20717

Given by (IV) vein

Sponsors

Collaborators (1)

Bayer
All Listed Sponsors
collaborator

Xencor, Inc.

INDUSTRY

collaborator

Bayer

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT05900648 - Regorafenib and XmAb20717 in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy (RX-CROME) | Biotech Hunter | Biotech Hunter